Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Global Good and Motic Announce AI-Powered Microscope at MEDICA 2017

By LabMedica International staff writers
Posted on 15 Nov 2017
Advanced microscope designer and manufacturer Motic China Group Co., Ltd. More...
(Xiamen, China), has announced at MEDICA 2017 that it will partner with the Global Good Fund (Bellevue, WA, USA), a collaboration between Intellectual Ventures and Bill Gates, to develop technologies for humanitarian impact. The collaboration will create and distribute the EasyScan GO, a breakthrough AI-powered microscope to fight the spread of drug-resistant malaria and assist in case management.

Motic specializes in manufacturing conventional compound microscopes, while Global Good is dedicated to inventing technology for humanitarian impact by collaborating with leading humanitarian organizations, forward-looking governments, research institutions, and corporate and private sector partners. Both Motic and Global Good will collaborate to create and distribute the EasyScan GO AI-powered microscope, which uses custom image recognition software to identify and count malaria parasites in a blood smear in as little as 20 minutes.

Accurate detection of severe and drug-resistant cases requires analysis of a blood smear by a WHO-certified expert microscopist, which takes roughly 20 minutes per slide. Automating the process with an intelligent microscope can alleviate the shortfall of trained personnel in under-resourced countries. Field tests of an early prototype of the microscope presented at the International Conference on Computer Vision (ICCV) showed that the machine-learning algorithm developed by Global Good is as reliable as an expert microscopist.

The EasyScan GO is currently being trained to recognize all species of malaria and other parasites and traits commonly found on a blood film, including Chagas disease, microfilaria and sickle cell. The team will also explore its application to other sample types, such as sputum, feces and tissue, as well some forms of cancer.

“This collaboration, combining Global Good’s impact invention focus with Motic’s engineering, manufacturing and distribution capabilities, represents the type of innovative healthcare solution that is needed to improve health in emerging and low-income markets,” said Maurizio Vecchione, Intellectual Ventures’ Executive Vice President of Global Good and Research. “By distributing and commercializing an intelligent microscope, Global Good and Motic are creating a future where quality diagnosis of multiple diseases is within reach for everyone everywhere.”

“Malaria is one of the hardest diseases to identify on a microscope slide,” said David Bell, Director of Global Health Technologies supporting Global Good. “By putting machine learning-enabled microscopes in the hands of laboratory technicians, we can overcome two major barriers to combating the mutating parasite—improving diagnosis in case management and standardizing detection across geographies and time.”

“Our goal in integrating Global Good’s advanced software into Motic’s high-quality, affordable digital slide scanner is to simplify and standardize malaria detection,” said Richard Yeung, Vice President of Motic China. “Success with the most difficult-to-identify disease paves the way for the EasyScan product line to excel at almost any microscopy task and to detect other major diseases that affect developed and emerging markets alike.”


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.